Abstract
The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Current Topics in Medicinal Chemistry
Title: Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands
Volume: 6 Issue: 12
Author(s): Carsten Carlberg and Ferdinand Molnar
Affiliation:
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Abstract: The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Export Options
About this article
Cite this article as:
Carlberg Carsten and Molnar Ferdinand, Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864908
DOI https://dx.doi.org/10.2174/156802606777864908 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Cross-Talk between Oxidative Stress and Pro-Inflammatory Cytokines in Acute Pancreatitis: A Key Role for Protein Phosphatases
Current Pharmaceutical Design Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
Current Drug Targets Caffeic Acid Phenethyl Ester Restores Adipocyte Gene Profile Expression Following Lipopolysaccharide Treatment
Letters in Drug Design & Discovery Subject Index to Volume 11
Protein & Peptide Letters Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design The Mammalian Innate Immune System: Potential Targets for Drug Development
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Review of Type 2 Diabetes Mellitus Predisposing Genes
Current Diabetes Reviews Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)